Abstract
1 An open clinical trial of indoramin, a new antihypertensive agent with α-adrenoreceptor blocking properties, in 27 patients with mild to moderate hypertension, showed good blood pressure reduction, no significant change in heart rate, and only mild side-effects.
2 A comparison of indoramin and methyldopa in the treatment of mild and moderate essential hypertension in 31 middle-aged patients was made by means of a double-blind crossover trial.
3 Satisfactory control of systolic and diastolic blood pressure, in the standing and supine positions, was achieved by both drugs. With a mean dose of 158±9 mg per day of indoramin the average fall in supine and standing blood pressures was 16/6 and 16/8 mm Hg respectively. Equivalent values for methyldopa, with a mean dose of 1 540±90 mg per day, were 21/8 and 26/13 mm Hg. Values for the two drugs are not significantly different.
4 There were no significant differences between the two drugs in their effect on the heart rate or in the incidence of side-effects.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Kramer R., Rosendorff C., Bloom D. Clinical evaluation of indoramin as the sole agent for the treatment of hypertension. S Afr Med J. 1974 Aug 3;48(37):1569–1572. [PubMed] [Google Scholar]
- Rosendorff C. Comparison of indoramin and methyldopa in hypertension. S Afr Med J. 1976 May 8;50(20):764–768. [PubMed] [Google Scholar]
- Wright B. M., Dore C. F. A random-zero sphygmomanometer. Lancet. 1970 Feb 14;1(7642):337–338. doi: 10.1016/s0140-6736(70)90709-9. [DOI] [PubMed] [Google Scholar]